ライフサイエンスコーパス: platelet-rich plasma

1 donor's blood samples (both whole blood and platelet-rich plasma).

2 imilar to that observed in vitro using mouse platelet rich plasma.

3 ergizes with soluble collagen in aggregating platelet-rich plasma.

4 bility to inhibit ADP-induced aggregation in platelet-rich plasma.

5 o study activation of isolated platelets and platelet-rich plasma.

6 counts for approximately 20% of total VWF in platelet-rich plasma.

7 DP-induced aggregation of human platelets in platelet-rich plasma.

8 extracellular protein substrates of ERp57 in platelet-rich plasma.

9 nic acid-induced platelet aggregation in rat platelet-rich plasma.

10 ntent of anandamide in either macrophages or platelet-rich plasma.

11 er the stent and was sprayed with autologous platelet-rich plasma adhesive gel.

12 RPAI-1 inhibits in vitro the ADP-dependent platelet-rich plasma aggregation by collagen (COLL), TRA

13 RPAI-1 inhibits human platelet-rich plasma aggregation triggered by low concen

14 ibition of aggregation of human platelets in platelet rich plasma, an IC50 of 6.8 nM for the inhibiti

15 orn trypsin inhibitor-treated whole blood or platelet rich plasma and subsequent array scanning via a

16 togenous bone and anorganic bovine bone with platelet-rich plasma and a bioabsorbable collagen membra

17 n of intra-articular cell therapies (such as platelet-rich plasma and bone marrow aspirate concentrat

18 telet aggregation in response to collagen in platelet-rich plasma and firm adhesion on VWF under arte

19 antiplatelet activity both in vitro in human platelet-rich plasma and in vivo in mice.

20 Platelet-rich plasma and microneedling have been investi

21 sional injections of autologous concentrated platelet-rich plasma and minoxidil showed some benefit i

22 ain antioxidants, anti-inflammatory drugs or platelet-rich plasma and new synthetic synovial fluid ad

23 arkedly enhanced thrombin generation in both platelet-rich plasma and platelet-poor plasma, indicatin

24 ysiologically relevant conditions such as in platelet-rich plasma and whole blood.

25 Thrombin generation in platelet-rich plasma and whole-blood clot formation were

26 ibition of platelet aggregation in the human platelet rich plasma assay with IC(5)(0) values below 50

27 tivates human VWF and induces aggregation of platelet-rich plasma at submicromolar concentrations.

28 hat fails to inhibit platelet aggregation in platelet-rich plasma, blocked the inhibitory effect of t

29 cally treated by amniotic membrane graft and platelet-rich plasma clot.

30 cal treatment by amniotic membrane graft and platelet-rich plasma clot.

31 Also, in CypD-deficient platelet-rich plasma, clot retraction was altered.

32 itro Abeta40 also increased the stiffness of platelet-rich plasma clots in the presence of FXIIIa.

33 nt with a single injection of intratendinous platelet-rich plasma, compared with insertion of a subcu

34 llograft (ADM) to that of a CPT plus ADM and platelet-rich plasma (CPT/PRP) 4 months post-surgically.

35 This study evaluates the influence of platelet-rich plasma derived from bone marrow aspirate (

36 inced the Canadian Blood Services to abandon platelet-rich-plasma-derived concentrates.

37 groups: demineralized freeze dried bone with platelet-rich plasma (DFDB + PRP), DFDB alone, and no tr

38 se of autologous fibrin membrane and the eye platelet-rich plasma (E-PRP) clot could be considered as

39 ncoated stents were then immersed in porcine platelet-rich plasma for two min and the platelet cyclic

40 PT was performed ex vivo by mixing platelet-rich plasma from blood sampling performed at ba

41 Unlike fibrinogen-deficient mice, platelet-rich plasma from Fib(AEK) mice supported normal

42 Blood or platelet-rich plasma from healthy volunteers stimulated

43 ated primary glomerular endothelial cells to platelet-rich plasma from patients, or patient platelet-

44 hibited when compared to the wild-type using platelet-rich plasma from the principal donor, but adhes

45 eatment of control neutrophils with COVID-19 platelet-rich plasma generated TF-bearing NETs that indu

46 erse events compared between patients in the platelet-rich plasma group vs the sham group were inject

47 luorescence spectroscopy) on whole blood and platelet-rich plasma indicate that exogenous alphaSyn ha

48 A single intratendinous platelet-rich plasma injection (n = 121) or a single sha

49 40 people from 24 sites assigned to either a platelet-rich plasma injection or a sham injection betwe

50 ment protocols, and clinician credentials of platelet-rich plasma injection therapy for erectile dysf

51 dinopathy, to assess the effects of a single platelet-rich plasma injection, compared with sham injec

52 ckwave therapy, corticosteroid injection, or platelet-rich plasma injection.

53 Platelet-rich plasma injections are used as a treatment

54 l of PVR in which cells were coinjected with platelet-rich plasma into the vitreous.

55 Injection of platelet-rich plasma is circumstantially considered an a

56 Platelet-rich plasma mitochondrial activity, protein exp

57 Platelet-rich plasma obtained from healthy (PRP) or tumo

58 of blood microparticles (MPs) obtained from platelet-rich plasma of healthy individuals was characte

59 anufacture of whole-blood-derived platelets (platelet-rich plasma or buffy coat intermediate steps) r

60 Among 240 patients assigned to a platelet-rich plasma or sham injection (mean age, 52 yea

61 Shear-induced GPVI shedding also occurred in platelet-rich plasma or washed platelets isolated from a

62 Human-citrated platelet-rich plasma or washed platelets were subjected

63 PMPs were isolated from platelet-rich plasma or were generated by activating was

64 nts or sample volumes can be used, either of platelet-rich plasma or whole blood from human subjects

65 exposure upon agonist-induced activation in platelet-rich plasma or whole blood whereas LPS(SM) and

66 r in agonist-induced aggregation measured in platelet-rich plasma or with washed platelets.

67 ormed in platelets, platelet microparticles, platelet-rich plasma, platelet-poor plasma, and serum.

68 platelet aggregation as measured in a human platelet rich plasma (PRP) assay.

69 to assess the efficacy of the injections of platelet rich plasma (PRP) for the treatment of severe d

70 th PMN and PMN-RBC combinations suspended in platelet rich plasma (PRP) than in platelet poor plasma

71 played inhibition of platelet aggregation in platelet rich plasma (PRP) with an IC(50) value of 53 nM

72 In platelet rich plasma (PRP), progressive APC resistance w

73 ADP stimulated human platelet aggregation in platelet rich plasma (PRP).

74 ration time (TGT) coagulation assay in human platelet rich plasma (PRP).

75 as to evaluate the regenerative influence of platelet-rich plasma (PRP) added to xenogenic bone graft

76 ion of CD62P by wild-type mouse platelets in platelet-rich plasma (PRP) and caused their secretion of

77 against PAR4 activation by gamma-thrombin in platelet-rich plasma (PRP) and greater than 2500-fold se

78 procoagulant potential of human platelets in platelet-rich plasma (PRP) and in purified systems.

79 Platelet-rich plasma (PRP) and platelet-poor plasma (PPP

80 lyze the content and specific effect of both platelet-rich plasma (PRP) and platelet-poor plasma (PPP

81 The comparison used platelet-rich plasma (PRP) and platelet-poor plasma (PPP

82 Platelet-rich plasma (PRP) and platelet-poor plasma (PPP

83 The antimicrobial activities of platelet-rich plasma (PRP) and related plasma preparatio

84 encouraging results reported with regards to Platelet-rich plasma (PRP) application in osteoarthritis

85 Autologous blood-derived products such as platelet-rich plasma (PRP) are widely used to treat musc

86 with an amniotic membrane graft (AMG) and a platelet-rich plasma (PRP) clot, and the anterior chambe

87 nhanced by 127% (P < 0.001) in study patient platelet-rich plasma (PRP) compared to control PRP and c

88 Platelet-rich plasma (PRP) consists of platelet-derived

89 Platelet-rich plasma (PRP) contains a number of biologic

90 lcium sulfate hemihydrate (MGCSH) mixed with platelet-rich plasma (PRP) for extraction socket preserv

91 Most clinical guidelines do not recommend platelet-rich plasma (PRP) for knee osteoarthritis (OA)

92 Platelet-rich plasma (PRP) from normal mice was able to

93 rombin burst in response to tissue factor in platelet-rich plasma (PRP) from patients with mild or mo

94 Platelet-rich plasma (PRP) harbors growth factors identi

95 Platelet-rich plasma (PRP) has been promoted as a surgic

96 e mineral (NBM) with and without addition of platelet-rich plasma (PRP) has been shown to result in s

97 The utilization of platelet-rich plasma (PRP) has exhibited potential as a

98 ch surrounding intra-articular injections of platelet-rich plasma (PRP) has not produced clear eviden

99 hput microfluidic removal of leukocytes from platelet-rich plasma (PRP) in a continuous flow regime.

100 of autologous platelet-rich fibrin (PRF) and platelet-rich plasma (PRP) in the treatment of intrabony

101 fective nonsurgical interventions exist, but platelet-rich plasma (PRP) injections are widely used, w

102 al benefits provided by the incorporation of platelet-rich plasma (PRP) into a regenerative protocol

103 Platelet-rich plasma (PRP) is a milieu of bioactive fact

104 Platelet-rich plasma (PRP) is used to stimulate the repa

105 Platelet-rich plasma (PRP) is widely used for many clini

106 Platelet-rich plasma (PRP) is widely used for osteoarthr

107 Platelet-rich plasma (PRP) promotes regeneration of bone

108 Calibrated thrombin assays using platelet-rich plasma (PRP) showed that tissue factor-tri

109 of recalcified platelet-free plasma (PFP) or platelet-rich plasma (PRP) supplemented with corn trypsi

110 al intrabony defects, the benefits of adding platelet-rich plasma (PRP) to a bone replacement graftin

111 plored through a spectrophotometric assay on platelet-rich plasma (PRP) treated with the thromboxane

112 Citrated platelet-rich plasma (PRP) turbidimetry is used for asse

113 Platelet-rich plasma (PRP) was prepared from 28 healthy

114 Blood samples were collected and platelet-rich plasma (PRP) was prepared.

115 Whole blood (WB) and platelet-rich plasma (PRP) were perfused at high shear r

116 aggregation tests (PATs) were performed with platelet-rich plasma (PRP), a shorter lag time was measu

117 Platelet-rich plasma (PRP), an autologous derivative of

118 Autologous bone marrow concentrate (BMC), platelet-rich plasma (PRP), and platelet lysate (PL) hav

119 A combination of platelet-rich plasma (PRP), bovine porous bone mineral (

120 Platelet-rich plasma (PRP), containing autologous growth

121 Coupled with platelet-rich plasma (PRP), known for its regenerative p

122 tomorphometrically analyzes the influence of platelet-rich plasma (PRP), low-level laser therapy (LLL

123 ractionated to yield red blood cells (RBCs), platelet-rich plasma (PRP), platelet-poor plasma (PPP),

124 Recent reports suggest that platelet-rich plasma (PRP), presumably high in levels of

125 In human platelet-rich plasma (PRP), RvE1 selectively blocked bot

126 ng of recombinant human TPO (rhTPO) to human platelet-rich plasma (PRP), washed platelets (WP), and c

127 sensitive for detecting HIT antibodies than platelet-rich plasma (PRP)-based assays.

128 activation occurred during leukodepletion of platelet-rich plasma (PRP).

129 FXI-depleted plasma and markedly enhanced in platelet-rich plasma (PRP).

130 was modified with PAR4-AP and incubated with platelet-rich plasma (PRP).

131 PVR was induced by the injection of RCFs and platelet-rich plasma (PRP).

132 specifically in VAT, in addition to elevated platelet-rich-plasma (PRP) NPY, compared to control fema

133 ogic agent (EMD, platelet-rich fibrin [PRF], platelet-rich plasma [PRP] or rhPDGF-BB) played a signif

134 12-hydroxyeicosatetraenoic acid to P-12LO-/- platelet-rich plasma rescues the hyperresponsive phenoty

135 Platelet aggregation assays with citrated platelet-rich plasma reveal that the primary and seconda

136 d at baseline in increasing proportions with platelet-rich plasma sampled 4 hours after loading dose.

137 ation, including the use of gene therapy and platelet-rich plasma scaffolds, are also discussed.

138 ing, hydrogel-coated PVC membranes soaked in platelet-rich plasma showed less adhesion and activation

139 Platelet-rich plasma showed markedly higher levels of mi

140 ctor Xa-inhibited (250 nM apixaban), diluted platelet rich plasma that had been loaded with the calci

141 ld be prevented by simply reducing the pH of platelet-rich plasma to about 6.5 prior to centrifugatio

142 erous modifications from whole blood-derived platelet-rich plasma to apheresis-derived platelet conce

143 Using gel-filtered platelets derived from platelet-rich plasma treated with alpha-tocopherol (500

144 r, second-wave aggregation induced by MDC in platelet-rich plasma was inhibited by aspirin, ADP scave

145 Platelet-rich plasma was obtained for aggregometry induc

146 Differential levels of endotoxin in platelet-rich plasma were detected using the limulus ame

147 the coagulation cascade in platelet poor or platelet-rich plasma, when activation was initiated by t

148 However, in platelet-rich plasma, where formation of both Tx and PGD

149 roparticles in megakaryocyte cultures and in platelet-rich plasma, which are predominantly derived fr

150 atelets derived from apheresis compared with platelet-rich plasma whole-blood-derived platelets.

151 Complementary isolated human platelet, platelet-rich plasma, whole blood, and animal model stud

152 ma cofactor, because a 35-hour incubation of platelet-rich plasma with 125I-factor V showed no specif